BidaskClub upgraded shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) from a sell rating to a hold rating in a research note released on Friday morning.
Other analysts also recently issued research reports about the company. Zacks Investment Research raised Revance Therapeutics from a hold rating to a buy rating and set a $26.00 price objective on the stock in a research note on Tuesday, August 15th. Cantor Fitzgerald initiated coverage on Revance Therapeutics in a research report on Thursday, July 20th. They set an overweight rating and a $50.00 target price on the stock. Aegis reissued a buy rating and set a $36.00 target price (up previously from $28.00) on shares of Revance Therapeutics in a research report on Friday, May 19th. ValuEngine raised Revance Therapeutics from a sell rating to a hold rating in a research report on Friday, June 9th. Finally, Piper Jaffray Companies set a $28.00 target price on Revance Therapeutics and gave the company a buy rating in a research report on Wednesday, July 26th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Revance Therapeutics has a consensus rating of Buy and a consensus price target of $35.00.
Revance Therapeutics (NASDAQ RVNC) opened at 23.15 on Friday. The company has a 50 day moving average of $23.99 and a 200 day moving average of $22.04. The company’s market capitalization is $713.46 million. Revance Therapeutics has a 52-week low of $12.35 and a 52-week high of $28.30.
Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.93) by $0.03. Revance Therapeutics had a negative return on equity of 55.21% and a negative net margin of 32,936.67%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. During the same quarter in the previous year, the company posted ($0.88) EPS. The company’s revenue was up .0% compared to the same quarter last year. On average, equities research analysts forecast that Revance Therapeutics will post ($3.75) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Revance Therapeutics, Inc. (RVNC) Raised to “Hold” at BidaskClub” was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://transcriptdaily.com/2017/08/21/revance-therapeutics-inc-rvnc-raised-to-hold-at-bidaskclub.html.
In related news, CEO L Daniel Browne sold 19,713 shares of the company’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $20.35, for a total transaction of $401,159.55. Following the completion of the sale, the chief executive officer now directly owns 183,932 shares in the company, valued at approximately $3,743,016.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 18.86% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of RVNC. Geode Capital Management LLC boosted its stake in shares of Revance Therapeutics by 16.4% in the first quarter. Geode Capital Management LLC now owns 178,435 shares of the biopharmaceutical company’s stock worth $3,711,000 after buying an additional 25,075 shares during the period. Vanguard Group Inc. boosted its stake in shares of Revance Therapeutics by 5.1% in the first quarter. Vanguard Group Inc. now owns 868,118 shares of the biopharmaceutical company’s stock worth $18,056,000 after buying an additional 42,466 shares during the period. FMR LLC boosted its stake in shares of Revance Therapeutics by 216.9% in the first quarter. FMR LLC now owns 316,900 shares of the biopharmaceutical company’s stock worth $6,592,000 after buying an additional 216,900 shares during the period. American International Group Inc. boosted its stake in shares of Revance Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 834 shares during the period. Finally, Victory Capital Management Inc. bought a new stake in shares of Revance Therapeutics during the first quarter worth $739,000. Hedge funds and other institutional investors own 87.94% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.